CN101396339B - Novel degradable lacrimal passage plug and preparation method thereof - Google Patents
Novel degradable lacrimal passage plug and preparation method thereof Download PDFInfo
- Publication number
- CN101396339B CN101396339B CN2008102281818A CN200810228181A CN101396339B CN 101396339 B CN101396339 B CN 101396339B CN 2008102281818 A CN2008102281818 A CN 2008102281818A CN 200810228181 A CN200810228181 A CN 200810228181A CN 101396339 B CN101396339 B CN 101396339B
- Authority
- CN
- China
- Prior art keywords
- lacrimal passage
- chitosan
- preparation
- concentration
- alginic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a novel degradable lacrimal passage embolism applied in the medical industry and a preparation method thereof. A drug-loaded degradable lacrimal passage contains sodium alginate as a main raw material and hydrochloride-calcium chloride or calcium chloride water as coagulator. A pressure pump is used for preparing continuous alginic acid-calcium alginate filaments with the diameter of 0.5 to 2.0mm, chitosan-diluted acetum is used for soaking and decorating to obtain alginic acid-calcium alginate-chitosan filaments which are cut into columns with certain length after being dehydrated, thus obtaining the degradable lacrimal passage embolism which can be implanted into the lacrimal passage for the lacrimal passage embolization. The lacrimal passage embolism has good biocompatibility and can be loaded with certain quantity of bacteriophage and anti-inflammatory and anti-proliferation drugs to reduce complications such as partial inflammation, wrapping and the like after being implanted, and the degrading period of the lacrimal passage embolism is adjusted by adjusting the concentration of chitosan-diluted acetum decoration solution and the soaking time.
Description
Technical field:
The present invention relates to a kind of lacrimal duct embolus that is used for the treatment of xerophthalmia and preparation method thereof, especially relating to the sodium alginate is primary raw material, and preparing with alginic acid, chitosan, calcium alginate is degradable lacrimal passage plug of main component and preparation method thereof.
Background technology: now, the incidence rate of xerophthalmia increases year by year.Xerophthalmia is meant because the tear film that causes unusually of the amount of tear or matter is unstable and the eye surface damage, thereby causes a class disease of ophthalmic uncomfortable symptom.The investigation of the U.S. shows in 65～84 years old crowd, have 14.6%, and promptly 4,300,000 population is suffered from xerophthalmia.Though do not have clear and definite xerophthalmia Epidemiological study result so far in China, based on the sanitary condition and the ambient condition of China, its sickness rate may be higher than the U.S..Main method to this type of persons suffering from ocular disorders treatment is: 1. replenish tear, promptly the replacement therapy of tear composition comprises the application of artificial tears and oneself serum; 2. preserve tear, as wear wet room mirror, row lacrimal passage thromboembolism etc.
For obstinate xerophthalmia, the lacrimal passage thromboembolism is still present best method clinically.To be tear be expelled to the anatomical passageway of nasal cavity from the eye table to lacrimal passage, by it is blocked, more kept the tear of self and played the effect of treatment at the eye table.The method of initial sealing lacrimal passage is to use hot lacrimal point to burn, and this method is simple and effective, but can cause cicatrix, and pain is arranged, and is simultaneously irreversible.Occurred being used to block the lacrimal duct embolus of lacrimal passage in recent years, behind the implantation lacrimal passage, its mechanical blockage effect has reduced the discharge of tear, now is used for clinical mainly contain two kinds (all originating from the U.S.): permanent type and degradable type.The former is made by silica gel, and after the implantation, the effect of lacrimal passage thromboembolism is permanent; The latter makes for collagen, implants back regular period degradable and makes lacrimal passage logical again, is mainly used in short term tests treatment and seasonal xerophthalmia.The appearance of lacrimal duct embolus makes the lacrimal passage Embolization become reversible operation, can take out at any time.Existing lacrimal duct embolus is import, costs an arm and a leg complicated process of preparation, it is raw material that the degradation-type embolus mostly is animal collagen, implant back slippage easily, and degradation cycle lacks (an about week), the generation of complication such as local inflammation after certain implantation, parcel is arranged in addition.Therefore, develop a kind of novel degradable lacrimal passage plug and preparation method thereof is home and abroad new problem anxious to be solved always.
Summary of the invention:
In order to solve the problem of above-mentioned existence, the present invention a kind of novel degradation-type lacrimal duct embolus is provided, the lacrimal passage embolotherapy, the severe dry eye patients that are mainly used in the moderate dry eye patients are implanted the preceding experimental treatment of permanent embolus and the treatment of seasonal xerophthalmia, can be written into medicine in the embolus, reduce local inflammation, parcel complication, and implantation after rehydration can expand, reduce the generation of embolus slippage situation, the preparation method of embolus is simple, cost is lower, more easily realize a kind of novel degradable lacrimal passage plug of industrialization and preparation method thereof.
The object of the present invention is achieved like this: a kind of novel degradable lacrimal passage plug and preparation method thereof, described lacrimal duct embolus is the preparation raw material with the sodium alginate, the composition of finished product comprises alginic acid, chitosan and calcium alginate, and its weight ratio is an alginic acid: chitosan: calcium alginate is 1: 0.1: 0.3～1: 1: 0.7; Lacrimal duct embolus can be written into antiinflammatory and antibacterials, its weight ratio is an alginic acid: chitosan: calcium alginate: medicine 1: 0.1: 0.3: 0.005～1: 1: 0.7: 0.3, described medicine is dexamethasone, a hydrocortisone in the anti-inflammatory drug, one or more combination of gentamycin, tobramycin in the antibiotics; The alginic acid of lacrimal duct embolus, calcium alginate molecular weight are 20～650,000, and the chitosan molecule amount is 15～550,000, and deacetylation is 70～95%; Its physical form of lacrimal duct embolus is long 1.0～2.5mm, and diameter 0.2～1.0mm's is cylindrical, and suction back volume is inflatable to be original 2.0～2.5 times; The preparation method of degradable lacrimal passage plug is as follows: (1) adopt molecular weight be 20～650,000 biologys absorbable sodium alginate be dissolved in normal saline, obtain the high viscosity solution that concentration is 3～10wt%, solution centrifugal or vacuumize degassing bubble is obtained preparing stock solution, with the air pressure of 0.2～0.8Mpa it is pressed into the CaCl that concentration is 5～10wt% gradually with special compression pump
2In the solution; Leave standstill the alginic acid one calcium alginate filament that obtained successive diameter 0.5～2.0mm in 30 minutes; Filament is washed, placing deacetylation then is that 70～95% concentration is that the aqueous solution of 0.5～3.5wt% chitosan and 0.5～5wt% spirit of vinegar soaks and modifies, and to alginic acid: chitosan: the calcium alginate weight ratio is that take out 1: 0.1: 0.3～1: 1: 0.7 back; Filament with washing of 75% alcoholic solution and gradient dehydration, is used the freeze dryer lyophilizing then, obtain the filament that diameter is 0.2～1.0mm, being cut to length is 1.0～2.5mm, the cylinder of diameter 0.2～1.0mm, and cobalt 60 sterilizations, envelope is standby; The preparation method of degradable lacrimal passage plug, wherein concentration is can add antiinflammatory and the antibacterials that concentration is 0.1～10wt% in the aqueous solution of 0.5～3.5wt% chitosan and 0.5～5wt% spirit of vinegar, so that be written into relative medicine in the product; The preparation method of degradable lacrimal passage plug, wherein concentration is can add antiinflammatory and the antibacterials that concentration is 0.1～10wt% in the high viscosity sodium alginate soln of 3～10wt%, so that be written into relative medicine in the product.
Main points of the present invention are its product and preparation method.Its preparation principle is, the composition of degradable lacrimal passage plug of the present invention is alginic acid, chitosan, calcium alginate, all have natural component at nature, studies show that in a large number they all have effects such as certain antiinflammatory, hemostasis, anti-cicatrix, have excellent biological compatibility, in vivo degradable, no antigen, not having harmful catabolite, can make its slow release behind the adding medicine in it, is medicine good slow release carrier.Embolus is implanted the back degradation cycle and can be controlled: primary amino radicals a large amount of on a large amount of carboxyls and the chitosan molecule chain formation polyelectrolyte that can mutually combine is arranged on the alginic acid strand, make the amino ionizing of chitosan simultaneously, thereby the antibiosis that has improved alginic acid and salt thereof and chitosan is managed brinish water solublity, make it absorb cycle stretch-out, so control the embolus that the content of chitosan in the raw material just can obtain good different degradation cycles.
A kind of novel degradable lacrimal passage plug and preparation method thereof compared with prior art, have novel science, processing technology lacrimal passage embolotherapy, severe dry eye patients superior, that be used for the moderate dry eye patients and implant the experimental treatment before the permanent embolus and the treatment of seasonal xerophthalmia, can be written into medicine in the embolus, reduce local inflammation, parcel complication, and implantation after rehydration can expand, reduce the generation of embolus slippage situation, the preparation method of embolus is simple, cost is lower, more easily realize advantage such as industrialization, will be widely used in the medical industry.
The specific embodiment:
Below in conjunction with embodiment the present invention is further described in detail:
The object of the present invention is achieved like this: a kind of novel degradable lacrimal passage plug and preparation method thereof, described lacrimal duct embolus is the preparation raw material with the sodium alginate, the composition of finished product comprises alginic acid, chitosan and calcium alginate, and its weight ratio is an alginic acid: chitosan: calcium alginate is 1: 0.1: 0.3～1: 1: 0.7; Lacrimal duct embolus can be written into antiinflammatory and antibacterials, its weight ratio is an alginic acid: chitosan: calcium alginate: medicine 1: 0.1: 0.3: 0.005～1: 1: 0.7: 0.3, described medicine is dexamethasone, a hydrocortisone in the anti-inflammatory drug, one or more combination of gentamycin, tobramycin in the antibiotics; The alginic acid of lacrimal duct embolus, calcium alginate molecular weight are 20～650,000, and the chitosan molecule amount is 15～550,000, and deacetylation is 70～95%; Its physical form of lacrimal duct embolus is long 1.0～2.5mm, and diameter 0.2～1.0mm's is cylindrical, and suction back volume is inflatable to be original 2.0～2.5 times; The preparation method of degradable lacrimal passage plug is as follows: (1) adopt molecular weight be 20～650,000 biologys absorbable sodium alginate be dissolved in normal saline, obtain the high viscosity solution that concentration is 3～10wt%, solution centrifugal or vacuumize degassing bubble is obtained preparing stock solution, with the air pressure of 0.2～0.8Mpa it is pressed into the CaCl that concentration is 5～10wt% gradually with special compression pump
2In the solution; Leave standstill the alginic acid-calcium alginate filament that obtained successive diameter 0.5～2.0mm in 30 minutes; Filament is washed, placing deacetylation then is that 70～95% concentration is that the aqueous solution of 0.5～3.5wt% chitosan and 0.5～5wt% spirit of vinegar soaks and modifies, and to alginic acid: chitosan: the calcium alginate weight ratio is that take out 1: 0.1: 0.3～1: 1: 0.7 back; Filament with washing of 75% alcoholic solution and gradient dehydration, is used the freeze dryer lyophilizing then, obtain the filament that diameter is 0.2～1.0mm, being cut to length is 1.0～2.5mm, the cylinder of diameter 0.2～1.0mm, and cobalt 60 sterilizations, envelope is standby; The preparation method of degradable lacrimal passage plug, wherein concentration is can add antiinflammatory and the antibacterials that concentration is 0.1～10wt% in the aqueous solution of 0.5～3.5wt% chitosan and 0.5～5wt% spirit of vinegar, so that be written into relative medicine in the product; The preparation method of degradable lacrimal passage plug, wherein concentration is can add antiinflammatory and the antibacterials that concentration is 0.1～10wt% in the high viscosity sodium alginate soln of 3～10wt%, so that be written into relative medicine in the product.
Embodiment one, adopting molecular weight is 500,000, and biology, absorbable sodium alginate was dissolved in tri-distilled water, obtained the high viscosity solution that concentration is 5wt%, the solution centrifugal deaeration is obtained preparing stock solution, be pressed into the CaCl that concentration is 5wt% gradually with the air pressure of 0.6Mpa with special compression pump
2In the solution; Leave standstill the alginic acid-calcium alginate filament that obtained successive diameter 1.5mm in 30 minutes.With filament washing, place then deacetylation be 75% concentration be the aqueous solution of 1.5wt% chitosan and 2wt% spirit of vinegar soak modify 30 minutes must alginic acid-chitin-alginic acid calcium filament.Filament is dewatered with the washing of 75wt% alcoholic solution and with the Different concentrations of alcohol solution gradient, and with the filament that obtains freeze dryer lyophilizing, cutting into length is 1.5mm, the cylinder of diameter 0.4mm, and cobalt 60 sterilizations, envelope is standby.
Embodiment two, adopting molecular weight is 350,000, biology, absorbable sodium alginate was dissolved in the tri-distilled water that contains the 2wt% dexamethasone injection, compound concentration is the high viscosity solution of 4wt%, the solution centrifugal deaeration is obtained preparing stock solution, be pressed into the CaCl that concentration is 6wt% gradually with the air pressure of 0.8Mpa with special compression pump
2In the solution; Leave standstill the sodium alginate-calcium alginate filament that obtained successive diameter 1.5mm in 30 minutes.Wash filament with tri-distilled water, placing deacetylation then is that 82% concentration is that the aqueous solution of 1wt% chitosan and 2wt% spirit of vinegar soaks, and leaves standstill chemical treatment in 20 minutes and gets alginic acid-chitin-alginic acid calcium filament.Filament is dewatered with 75wt% washing with alcohol and gradient, and with the filament that obtains freeze dryer lyophilizing, cutting into length is 1.0mm, the filament of diameter 0.3mm, and cobalt 60 sterilizations, envelope is standby.
Embodiment three, adopting molecular weight is 450,000, absorbable sodium alginate was dissolved in the aqueous solution that contains the 1.5wt% gentamycin and obtained the high viscosity solution that concentration is 5wt% biology, the solution vacuumizing and defoaming is obtained preparing stock solution, be pressed into the CaCl that concentration is 9wt% gradually with the air pressure of 0.3Mpa with special compression pump
2In the solution; Leave standstill the alginic acid-calcium alginate filament that obtained successive diameter 2.0mm in 30 minutes.Filament is washed with tri-distilled water, and placing deacetylation then is that 85% concentration is that the aqueous solution of 2.5wt% chitosan and 2.5wt% spirit of vinegar soaks, and leaves standstill chemical treatment in 20 minutes and gets alginic acid-chitin-alginic acid calcium filament.Filament is dewatered with washing of 75% alcoholic solution and gradient, and with the filament that obtains freeze dryer lyophilizing, cutting into length is 1.5mm, the filament of diameter 1.0mm, and cobalt 60 sterilizations, envelope is standby.
Embodiment four, adopting molecular weight is 550,000, biology, absorbable sodium alginate was dissolved in the tri-distilled water that contains 1.5% tobramycin, obtain the high viscosity solution that concentration is 6wt%, the solution centrifugal deaeration is obtained preparing stock solution, be pressed into the CaCl that concentration is 8wt% gradually with the air pressure of 0.6Mpa with special compression pump
2In the solution; Leave standstill the alginic acid-calcium alginate filament that obtained successive diameter 2.5mm in 20 minutes.Filament is washed with tri-distilled water, and placing deacetylation then is that 85% concentration is that the aqueous solution of 3wt% chitosan and 3wt% spirit of vinegar soaks, and leaves standstill chemical treatment in 15 minutes and gets alginic acid-chitin-alginic acid calcium filament.Filament is dewatered with washing of 75% alcoholic solution and gradient, and with the filament that obtains freeze dryer lyophilizing, cutting into length is 2.0mm, the filament of diameter 0.5mm, and cobalt 60 sterilizations, envelope is standby.
Embodiment five, adopting molecular weight is 600,000, absorbable sodium alginate was dissolved in and contained the 2wt% dexamethasone injection biology, in the tri-distilled water of 20,000 U gentamycins, obtain the high viscosity solution that concentration is 7wt%, the solution centrifugal deaeration is obtained preparing stock solution, be pressed into the CaCl that concentration is 9wt% gradually with the air pressure of 0.3Mpa with special compression pump
2In the solution; Leave standstill the sodium alginate-calcium alginate filament that obtained successive diameter 1.5mm in 10 minutes.With filament washing, placing deacetylation then is that 95% concentration is that the aqueous solution of 2.5wt% chitosan and 2wt% spirit of vinegar soaks, and leaves standstill chemical treatment in 15 minutes and gets alginic acid-chitin-alginic acid calcium filament.Filament is dewatered with washing of 75% alcoholic solution and gradient, and with the filament that obtains freeze dryer lyophilizing, cutting into length is 1.0mm, the filament of diameter 1.0mm, and cobalt 60 sterilizations, envelope is standby.
Embodiment six, adopting molecular weight is 650,000, absorbable sodium alginate was dissolved in and contained the 2wt% dexamethasone injection biology, in the 1.5wt% gentamycin tri-distilled water, obtain the high viscosity solution that concentration is 8wt%, the solution centrifugal deaeration is obtained homogenate, be pressed into the CaCl that concentration is 10wt% gradually with the air pressure of 0.8Mpa with special compression pump
2In the solution; Leave standstill the sodium alginate-calcium alginate filament that obtained successive diameter 1.5mm in 30 minutes.With filament washing, placing deacetylation then is that 95% concentration is that the aqueous solution of 3wt% chitosan and 2wt% spirit of vinegar soaks, and leaves standstill chemical treatment in 20 minutes and gets alginic acid-chitin-alginic acid calcium filament.Filament is dewatered with washing of 75% alcoholic solution and gradient, and with the filament that obtains freeze dryer lyophilizing, cutting into length is 1.5mm, the filament of diameter 0.7mm, and cobalt 60 sterilizations, envelope is standby.
Below the present invention is further described in detail: the embolus of above each embodiment preparation, physical form is small cylinder, and length is 1.0～2.5mm, and diameter is the cylindrical of 0.2～1.0mm, to be fit to the implantation of different thicknesses lacrimal passage.Environment is observed lacrimal duct embolus of the present invention in the simulation human body lacrimal passage: the lacrimal duct embolus that the appeal method makes is inserted in the small test tube, add and contain in the normal saline of lysozyme (concentration is 1.7mg/ml), put into 37 ℃ of water baths, change liquid every day and observe its variation.The result: expansion rate is about 200～250% after the lacrimal duct embolus rehydration.The finished product embolus that embodiment 1 ~ 6 makes all can be degraded in 3 months fully, and its degradation cycle is different because of the concentration of chitosan dilute acetic acid solution, and the big more degradation cycle of its concentration is long more.Detect the normal saline of medicine carrying lacrimal duct embolus with high performance liquid chromatograph and change clothes liquid discovery, the existence that all can measure medicine when embolus is not degraded fully.Show after, need not take out and just can make lacrimal passage logical again, because of antiinflammatory, the anti-cicatrix of effect of chitosan self and the medicine that is loaded with the incidence rate of local inflammation and propagation parcel is reduced in addition from melting with lacrimal duct embolus implant into body lacrimal passage of the present invention.
The clinical report of a kind of novel degradable lacrimal passage plug and preparation method thereof: in selecting to be diagnosed as, patient's 60 examples of severe xerophthalmia, be divided into two groups by randomly assigne, each 30 example of artificial tears's treatment group and lacrimal duct embolus treatment group.Artificial tears's treatment group gives hyaluronate sodium medicament for the eyes day four eye dripping treatments, and lacrimal duct embolus treatment group descends lacrimal point to implant the treatment of preparation lacrimal duct embolus.Followed up a case by regular visits to for 2 weeks, to carrying out lacrimal secretion amount, breakup time of tear film and cornea fluorescent staining scoring carrying out record before and after the treatment.
After two weeks, two groups of patient's eyes are done and are waited malaise symptoms that in various degree improvement is all arranged.After application SPSS13.0 software analysis treated for 2 weeks, the variation of each check result.Use pairing T check analysis, the lacrimal secretion amount before and after using artificial tear group and the treatment of lacrimal duct embolus treatment group does not all have significant difference (p＞0.05), illustrates that two kinds of treatments all can not increase patient's lacrimal secretion (table 1).Breakup time of tear film all prolongs before and after two groups of treatments, use pairing T check analysis, significant difference (p＜0.05) is arranged before and after two groups of patient treatments, and the result uses T check analysis in groups after two groups of medications, significant difference (p＜0.05) is also arranged, and visible lacrimal duct embolus treatment group prolongs breakup time of tear film and obviously is better than using the artificial tears to organize (table 2).Use pairing rank test analysis, fluorescent staining is clearly better before and after two groups of treatments, significant difference (p＜0.05) is arranged, 2 week two groups of fluorescent staining results in back use rank test analysis in groups, there was no significant difference (p＞0.05), explanation is for the treatment of this group dry eye patients corneal epithelium pathological changes, and lacrimal duct embolus has similar effect (table 3) with the artificial tears.
Table 1Schirmer result of the test (mm)
Table 2 breakup time of tear film (BUT) result (second)
Table 3 fluorescent staining result
The clinic trial preliminary conclusion: the lacrimal duct embolus that adopts the method for the invention to prepare is applied to clinical, and therapeutic effect is satisfied, does not find severe complication.
Claims (7)
1. novel degradable lacrimal passage plug, it is characterized in that: described lacrimal duct embolus is the preparation raw material with the sodium alginate, the composition of finished product comprises alginic acid, chitosan and calcium alginate, and its weight ratio is an alginic acid: chitosan: calcium alginate is 1: 0.1: 0.3～1: 1: 0.7.
2. a kind of novel degradable lacrimal passage plug according to claim 1, it is characterized in that: said lacrimal duct embolus is written into antiinflammatory and antibacterials, its weight ratio is an alginic acid: chitosan: calcium alginate: medicine 1: 0.1: 0.3: 0.005～1: 1: 0.7: 0.3, described medicine is dexamethasone, a hydrocortisone in the anti-inflammatory drug, one or more combination of gentamycin, tobramycin in the antibiotics.
3. a kind of novel degradable lacrimal passage plug according to claim 1 is characterized in that: the alginic acid of said lacrimal duct embolus, calcium alginate molecular weight are 20～650,000, and the chitosan molecule amount is 15～550,000, and deacetylation is 70～95%.
4. a kind of novel degradable lacrimal passage plug according to claim 1 is characterized in that: its physical form of said lacrimal duct embolus is long 1.0～2.5mm, and diameter 0.2～1.0mm's is cylindrical, and suction back volume is inflatable to be original 2.0～2.5 times.
5. the preparation method of a kind of novel degradable lacrimal passage plug according to claim 1, it is characterized in that: the preparation method of said degradable lacrimal passage plug is as follows: (1) adopt molecular weight be 20～650,000 biologys absorbable sodium alginate be dissolved in normal saline, obtain the high viscosity solution that concentration is 3～10wt%, solution centrifugal or vacuumize degassing bubble is obtained preparing stock solution, with the air pressure of 0.2～0.8Mpa it is pressed into the CaCl that concentration is 5～10wt% gradually with special compression pump
2In the solution; Leave standstill the alginic acid-calcium alginate filament that obtained successive diameter 0.5～2.0mm in 30 minutes; Filament is washed, placing deacetylation then is that 70～95% concentration is that the aqueous solution of 0.5～3.5wt% chitosan and 0.5～5wt% spirit of vinegar soaks and modifies, and to alginic acid: chitosan: the calcium alginate weight ratio is that take out 1: 0.1: 0.3～1: 1: 0.7 back; Filament with washing of 75% alcoholic solution and gradient dehydration, is used the freeze dryer lyophilizing then, obtain the filament that diameter is 0.2～1.0mm, being cut to length is 1.0～2.5mm, the cylinder of diameter 0.2～1.0mm, and cobalt 60 sterilizations, envelope is standby.
6. the preparation method of a kind of novel degradable lacrimal passage plug according to claim 5, it is characterized in that: the preparation method of said degradable lacrimal passage plug, wherein concentration is that to add concentration in the aqueous solution of 0.5～3.5wt% chitosan and 0.5～5wt% spirit of vinegar be antiinflammatory and the antibacterials of 0.1～10wt%, so that be written into relative medicine in the product.
7. the preparation method of a kind of novel degradable lacrimal passage plug according to claim 5, it is characterized in that: the preparation method of said degradable lacrimal passage plug, wherein concentration is that to add concentration in the high viscosity sodium alginate soln of 3～10wt% be antiinflammatory and the antibacterials of 0.1～10wt%, so that be written into relative medicine in the product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102281818A CN101396339B (en) | 2008-10-20 | 2008-10-20 | Novel degradable lacrimal passage plug and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102281818A CN101396339B (en) | 2008-10-20 | 2008-10-20 | Novel degradable lacrimal passage plug and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101396339A CN101396339A (en) | 2009-04-01 |
| CN101396339B true CN101396339B (en) | 2010-04-14 |
Family
ID=40515341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102281818A Active CN101396339B (en) | 2008-10-20 | 2008-10-20 | Novel degradable lacrimal passage plug and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101396339B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105664265A (en) * | 2016-01-28 | 2016-06-15 | 菏泽医学专科学校 | Novel degradable lacrimal plug and preparation method thereof |
| CN106074361B (en) * | 2016-07-14 | 2018-10-19 | 何伟 | A kind of anti-intraocular inflammation implant and its preparation method and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1724072A (en) * | 2005-07-12 | 2006-01-25 | 何伟 | Medicine-carried degradable type lacrimal duct embolus, and its prepn. method |
| CN1879607A (en) * | 2005-06-03 | 2006-12-20 | 北京圣医耀科技发展有限责任公司 | A sodium alginate microsphere vascular embolizing agent containing water soluble drug, its preparation and application |
| CN1907507A (en) * | 2006-08-30 | 2007-02-07 | 中国人民解放军军事医学科学院卫生装备研究所 | Lacrimal duct plug and its preparing process and use |
| CN1919362A (en) * | 2006-01-05 | 2007-02-28 | 天津市威曼生物材料有限公司 | Collagen short stick using for dacryosolen embolism |
| CN101130114A (en) * | 2007-09-06 | 2008-02-27 | 复旦大学 | Biological compatibility surface coating of implantation type medical instruments and coating method thereof |
-
2008
- 2008-10-20 CN CN2008102281818A patent/CN101396339B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879607A (en) * | 2005-06-03 | 2006-12-20 | 北京圣医耀科技发展有限责任公司 | A sodium alginate microsphere vascular embolizing agent containing water soluble drug, its preparation and application |
| CN1724072A (en) * | 2005-07-12 | 2006-01-25 | 何伟 | Medicine-carried degradable type lacrimal duct embolus, and its prepn. method |
| CN1919362A (en) * | 2006-01-05 | 2007-02-28 | 天津市威曼生物材料有限公司 | Collagen short stick using for dacryosolen embolism |
| CN1907507A (en) * | 2006-08-30 | 2007-02-07 | 中国人民解放军军事医学科学院卫生装备研究所 | Lacrimal duct plug and its preparing process and use |
| CN101130114A (en) * | 2007-09-06 | 2008-02-27 | 复旦大学 | Biological compatibility surface coating of implantation type medical instruments and coating method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 何伟，樊庆侠.一种新型可降解泪道栓子的研制与临床疗效评估.中华医学会第十二届全国眼科学术大会论文汇编.2007,713-714. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101396339A (en) | 2009-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pahuja et al. | Ocular drug delivery system: a reference to natural polymers | |
| US8501822B2 (en) | Ophthalmic composition containing alginic acid or salt thereof | |
| US20060110459A1 (en) | Triple natural polymer viscoelastic composition | |
| JPH10510293A (en) | Controlled release of miotic and mydriatic drugs in the anterior chamber | |
| JP7406634B2 (en) | Soluble polymer ophthalmic inserts with biodegradable polymers | |
| CA3137417C (en) | Dissolvable polymeric eye inserts and method of using same | |
| JP7473237B2 (en) | Compositions and methods for treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces - Patents.com | |
| WO2005097225A1 (en) | New viscoelastic composition, method of use and package | |
| CN109045063B (en) | In-situ injectable temperature-sensitive response water-soluble chitosan composite hydrogel for lacrimal passage embolism and preparation method and application thereof | |
| JP2019500944A (en) | Dissolvable nasal sinus sponge | |
| WO2014127007A1 (en) | Ophthalmic formulation derived from silk protein | |
| KR20060131938A (en) | New free-radical scavenger containing viscoelastic composition, methods of use and package | |
| CN100350978C (en) | Medicine-carried degradable type lacrimal duct embolus, and its prepn. method | |
| CN101396339B (en) | Novel degradable lacrimal passage plug and preparation method thereof | |
| KR100963611B1 (en) | Eye composition comprising alginic acid based compounds and method of preparing the same | |
| Sharma et al. | Ocular Bioadhesive Drug Delivery Systems and Their Applications | |
| RU2802441C1 (en) | Soluble polymeric ophthalmic inlays with biodegradable polymer | |
| US20230201030A1 (en) | Dissolvable medical device for drugs delivery | |
| Sajini et al. | Plant polysaccharides in ocular drug delivery | |
| Ali et al. | An insight of natural polymers in ocular drug delivery systems | |
| Pohja | Biomaterials for dry eye syndrome | |
| CN101219100A (en) | Medicine film for eyes and production method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENYANG SILVER SEA MEDICAL PRODUCTS CO., LTD. Free format text: FORMER OWNER: HE WEI Effective date: 20110316 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110163 NO. 36-36, SENLIN ROAD, QIPANSHAN DEVELOPMENT AREA, SHENYANG CITY, LIAONING PROVINCE TO: 110000 NO. 128, HUANGHE NORTH STREET, YUHONG DISTRICT, SHENYANG CITY, LIAONING PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110316 Address after: 110000, 128 North Main Street, Yuhong District, Shenyang, Liaoning, the Yellow River Patentee after: Shenyang Yinhai medical supplies Co., Ltd. Address before: 110163 No. 36-36 forest road, chessboard Development Zone, Liaoning, Shenyang Patentee before: He Wei |